Milestones for Kamada under deals with Chiesi and Baxalta

3 May 2016

Israeli plasma-derived protein therapeutics focused company Kamada (TASE: KMDA) says it has received two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Italy’s Chiesi Farmaceutici and the USA’s Baxalta (NYSE: BXLT). The news lifted Kamada’s shares by 5.6% to $4.15 on Monday.

Kamada received a milestone payment from Chiesi upon the filing of a Marketing Authorization Application with the European Medicines Agency for inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency (AATD). Under a 2012 accord, Chiesi is Kamada’s exclusive marketing and distribution partner for its inhaled AAT for the treatment of AATD in Europe.

In addition, Kamada received a milestone payment from Baxalta as a result of Baxalta achieving an undisclosed sales milestone for Glassia, Kamada's intravenous (IV) AAT treatment. Baxalta is Kamada’s strategic partner for the exclusive distribution of Glassia for all indications in the USA, Canada, Australia and New Zealand, under a collaboration signed in 2010 and expanded last year (The Pharma Letter October 17, 2015).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK